The European Medicines Agency (EMA) has published a template for applicants seeking entry into its pilot program for breakthrough medical devices, aiming to streamline the application process for technologies offering significant clinical advantages. The guidance, released on 28 April 2026, targets manufacturers of innovative devices in digital health, diagnostics, and therapeutics, as well as clinicians and patients who stand to benefit from expedited access to promising treatments.
The document, issued by EMA's Medical Devices Division, is a non-binding guidance template that outlines key recommendations for applicants. It advises providing detailed evidence of the device's innovative nature, robust clinical data supporting its benefits, and a clear development plan. The pilot operates under the EU's Medical Device Regulation (MDR), which governs the safety and performance of medical devices in the European market.
Policy orientations and trade-offs
The template reflects a balance between accelerating patient access to breakthrough technologies and maintaining rigorous safety and efficacy standards. By offering a structured application format, EMA aims to reduce administrative burden for innovators while ensuring that submissions contain sufficient evidence for regulatory assessment. However, the emphasis on detailed clinical data may pose challenges for smaller firms or early-stage technologies with limited trial results, potentially favouring larger manufacturers with more resources.
Impact on stakeholders
- Medical device manufacturers: The template provides clarity on expectations, potentially reducing application delays. However, the requirement for comprehensive clinical evidence could increase upfront costs, particularly for startups and SMEs.
- Clinicians and patients: Faster access to innovative devices could improve treatment outcomes, especially for conditions with limited existing options. The pilot may also foster earlier adoption of cutting-edge therapies.
- EU regulatory bodies: The structured approach may streamline EMA's review process, but evaluating novel technologies with limited real-world data could pose assessment challenges.
- National competent authorities: Harmonised application criteria may facilitate coordination across member states, though divergence in national implementation of the MDR could persist.
Expected institutional follow-up
EMA will accept applications under the pilot based on the template, with feedback from early applicants likely to inform future refinements. The agency may also issue additional guidance on specific device categories or data requirements as the pilot progresses. The European Commission and national authorities are expected to monitor the pilot's impact on market access and patient safety, potentially leading to legislative adjustments to the MDR framework.